Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients

• Published in: Radiation protection dosimetry 2015-03, Vol.163 (4), p.468-472
• Main Authors: Parlak, Yasemin, Gumuser, Gul, Sayit, Elvan
• Format: Article
• Language: English
• Subjects: Aged; Analgesics, Non-Narcotic - pharmacokinetics; Analgesics, Non-Narcotic - therapeutic use; Analgesics, Non-Narcotic - urine; Bone Neoplasms - metabolism; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Humans; Male; Metabolic Clearance Rate; Middle Aged; Occupational Exposure - analysis; Organometallic Compounds - pharmacokinetics; Organometallic Compounds - therapeutic use; Organometallic Compounds - urine; Organophosphorus Compounds - pharmacokinetics; Organophosphorus Compounds - therapeutic use; Organophosphorus Compounds - urine; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; Radiation Dosage; Radiopharmaceuticals - pharmacokinetics; Radiopharmaceuticals - therapeutic use; Radiopharmaceuticals - urine; Skin - radiation effects; Tissue Distribution
• ISSN: 0144-8420; 1742-3406
• DOI: 10.1093/rpd/ncu237

The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid ((153)Sm-EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff's finger. Urine samples were collected from 11 patients after intravenous injection of (153)Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 µSv h(-1) for within 1 h following (153)Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved (153)Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week.